# Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19

3

4 Raavi Gupta, M.D., Raag Agrawal, B.A., Zaheer Bukhari, M.D., Absia Jabbar, M.D.,

5 Donghai Wang, M.D. Ph.D., John Diks, M.D., Mohamed Alshal, M.D., Dokpe Yvonne

- 6 Emechebe, M.D., F. Charles Brunicardi, M.D., Jason M. Lazar, M.D., M.P.H., Robert
- 7 Chamberlain, M.B.B.S., M.P.H., Aaliya Burza, M.D., M.A. Haseeb, Ph.D.
- 8
- 9<sup>1.</sup> SUNY Downstate Medical Center, Departments of Pathology and Cell Biology,
- 10 Brooklyn, New York, (R.G., M.A.H.)
- <sup>2</sup> SUNY Downstate Medical Center, Departments of Pathology (R.A., Z.B., A.J., D.W.,
   J.D., M.A., D.Y.E.)
- <sup>3</sup> SUNY Downstate Medical Center, Department of Surgery (F.C.B.)
- <sup>4</sup> SUNY Downstate Medical Center, Department of Medicine, Division of Cardiology
   (J.M.L.)
- <sup>5</sup> SUNY Downstate Medical Center, Department of Anesthesiology (R.C.)
- <sup>6</sup> SUNY Downstate Medical Center, Department of Medicine, Division of Pulmonary
- 18 Medicine and Critical Care (A.B.)
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26 27
- 28
- 29
- 30
- 31
- 32 33
- 34
- 35
- 36
- 37
- 38
- 39 40
- 40 Correspondence:
- 41
- 43 Raavi Gupta, M.D.
- 44 450 Clarkson Ave. MSC #37,
- 45 Brooklyn, NY, 11203
- 46 raavi.gupta@downstate.edu

1

# 47 **ABSTRACT**

48

#### 49 Background

- 50 African-Americans/Blacks have suffered higher morbidity and mortality from COVID-19
- 51 than all other racial groups. This study aims to identify the causes of this health
- 52 disparity, determine prognostic indicators, and assess efficacy of treatment
- 53 interventions.

#### 54 55 **Method**

- 56 We performed a retrospective cohort study of clinical features and laboratory data of
- 57 COVID-19 patients admitted over a five-week period at the height of the pandemic in
- the United States. This study was performed at an urban academic medical center in
- 59 New York City, declared a COVID-only facility, serving a majority Black population
- 60

#### 61 Result

- 62 Of the 1,070 consecutive patients who tested positive for COVID-19, 496 critically ill
- 63 patients were hospitalized and included in the study. 88% of patients were Black; and a
- 64 majority (53%) were 61-80 years old with a mean body mass index in the "obese"
- range. 97% had one or more comorbidities. Hypertension was the most common (84%)
- 66 pre-existing condition followed by diabetes mellitus (57%) and chronic kidney disease
- 67 (24%). Patients with chronic kidney disease and end-stage renal disease who received
- 68 hemodialysis were found to have significantly lower mortality, then those who did not
- 69 receive it, suggesting benefit from hemodialysis (11%, OR, 0.35, CI, 0.17 0.69
- P=0.001). Age >60 years and coronary artery disease were independent predictors of
   mortality in multivariate analysis. Cox Proportional Hazards modeling for time to death
- 71 mortality in multivariate analysis. Cox Proportional Hazards modeling for time to deatr 72 demonstrated a significantly high ratio for COPD/Asthma, and favorable effects on
- 72 outcomes for pre-admission ACE inhibitors and ARBs. CRP (180, 283 mg/L), LDH
- 74 (551, 638 U/L), glucose (182, 163 mg/dL), procalcitonin (1.03, 1.68 ng/mL), and
- neutrophil / lymphocyte ratio (8.5, 10.0) were predictive of mortality on admission and at
- 76 48-96 hrs. Of the 496 inpatients, 48% died, one third of patients died within the first
- 77 three days of admission. 54/488 patients received invasive mechanical ventilation, of
- which 87% died and of the remaining patients, 32% died.

# 7980 CONCLUSIONS

- COVID-19 patients in our predominantly Black neighborhood had higher mortality, likely
   due to higher prevalence of comorbidities. Early dialysis and pre-admission intake of
   ACE inhibitors/ARBs improved patient outcomes. Early escalation of care based on
- 84 comorbidities and key laboratory indicators is critical for improving outcomes in African-
- 85 American patients.
- 86
- Key words: Health Disparities, COVID-19, African-Americans, Dialysis, ACE Inhibitors,
   ARBs, Comorbidities, Chronic Kidney Disease
- 89
- 90
- 91
- 92

# 93 Background

94

95 Coronavirus Disease 2019 (COVID-19), caused by infection with Severe Acute 96 Respiratory Syndrome Coronavirus-2, has been declared by the World Health 97 Organization to be a pandemic, with over five million confirmed cases.<sup>1</sup> New York became 98 the epicenter of the epidemic in the United States, accounting for more than 23% of the 99 total U.S. cases by the end of May, 2020.<sup>2</sup> Such burden of disease is of particular concern 90 since it disproportionately affects communities with considerable health disparities, where 91 African-Americans and Latinos constitute as much as 53% of the population.<sup>3</sup>

102

103 The spectrum of COVID-19 presentation ranges from mild influenza-like illness to life-104 threatening severe respiratory disease requiring ventilatory support.<sup>3</sup> Comorbid conditions such as hypertension, diabetes mellitus, pulmonary and heart diseases, and 105 demographic factors have been reported to influence outcomes.<sup>4–6</sup> However, the relative 106 107 influence of each of these comorbidities in different patient populations and age strata 108 has not been assessed, leading to variability in management and outcomes. Key 109 decisions in patient management such as the choice of antibiotic, blood pressure goals, 110 and perhaps most importantly, airway management strategies, have remained variable 111 across or within hospitals.

112

113 National health statistics have documented extensive health disparities for Black COVID-

- 19 patients. They suffer a three-fold greater infection rate, and a six-fold greater mortality rate than their white counterparts.<sup>7</sup> However, clinical features and laboratory data of prognostic significance from Black COVID-19 patients remain unexplored and undocumented. A range of cultural, linguistic, and healthcare access barriers have prevented clinical investigation. Our hospital, located in New York City, serves a predominantly Black population, and being declared a COVID-19 patients.
- 121

122 Here we explore the clinical aspects of COVID-19 and its outcomes in Black patients; we 123 also identify comorbidities and demographic factors that help explain the greater mortality from COVID-19 observed in this vulnerable population. This study evaluated clinical signs 124 125 and symptoms, laboratory indicators, and management strategies to develop a data-126 driven COVID-19 patient-care approach. We evaluated these factors at admission and at 127 48-96 hours after admission, as one-third of our patients died within the first few days of 128 admission, and we found early recognition of critical indicators pivotal in assessing risk of 129 mortality. To our knowledge, this is the only study that correlates early laboratory 130 indicators at two critical time points with outcomes. Therefore, our findings are expected 131 to provide an evidence-based resource for physicians to assess patient progress within 132 the first three days of hospitalization to direct patient management decisions.

133

# 134 Methods

135

This study analyzed COVID-19 patients hospitalized at the State University of New York (SUNY), Downstate Medical Center, Brooklyn, New York, that was designated a COVIDonly facility by the State of New York as of March 4th, 2020. The hospital is located in a

majority Black neighborhood with high rates of poverty.<sup>8</sup> This study was approved by the
 SUNY Downstate Institutional Review Board [1587476-1].

141

142 We examined 496 consecutively admitted COVID-19 patients during a five-week period 143 (March-April) when the hospital was under peak caseload and admission was reserved 144 for critically ill patients. COVID-19 diagnosis was based on clinical presentation and a 145 positive real-time reverse transcriptase polymerase chain reaction (rtPCR) from a 146 nasopharyngeal swab (Xpert Xpress SARS-CoV-2, Cepheid, Sunnyvale, CA). Patients 147 were admitted if deemed to be in respiratory distress (respiratory rate >22 breaths/min 148 and in need of supplemental oxygen to maintain oxygen saturation >92%), were 149 encephalopathic, or were judged sufficiently ill to require hospitalization. Only patients 150 with final clinical outcomes, such as discharge or expiration, were included. Patients with 151 "fluid overload" (due to missed dialysis), pregnancy, or those still hospitalized were 152 excluded from this analysis.

153

154 Demographic factors, comorbidities, presenting clinical symptoms, and outcomes 155 (discharge/death) were available for 496 patients. Of these, laboratory data were 156 recorded for 281 patients on admission or within 24 hr of hospitalization, and at a second 157 time point between 48-96 hr post-admission. Pre-admission medications were recorded 158 based on admission medication reconciliation by admitting physicians. Based on self-159 reported race/ethnicity, patients were grouped into Black and Others (White Hispanic/non-Hispanic and Asian). HIV-positive patients (with low CD4 counts) and 160 161 transplant recipients were categorized as "immunocompromised".

162

163 Patients were treated with hydroxychloroguine (200 mg twice a day, for five days) and 164 azithromycin (250 mg once a day, for five days). All patients received standard venous 165 thromboembolism prophylaxis with low-molecular weight heparin or direct oral 166 anticoagulants based on their creatinine clearance rate. Patients with elevated D-dimer received a full dose anticoagulation regimen. Hypoxia, a sign of Acute Respiratory 167 168 Distress Syndrome (ARDS), was monitored by a continuous pulse oximeter and with arterial blood gas measurements, and supplemental oxygen was provided as needed via 169 170 noninvasive ventilation. Patients with worsening respiratory distress despite supportive 171 care, as determined by declining pulse oximeter saturation, increasing respiratory rate, or 172 worsening partial pressure of arterial oxygen/percentage of inspired oxygen ratio) were 173 intubated and placed on mechanical ventilation. Patients who developed acute kidney 174 injury (AKI), defined as an absolute increase in serum creatinine greater than or equal to 175 0.3 mg/dL within 48 hr, with oliguria, with or without hyperkalemia and metabolic acidosis, 176 received hemodialysis.

177

Computational analysis was conducted using R (ver. 3.6.3).<sup>9</sup> Continuous variables are presented as median and interquartile range (IQR). Categorical variables such as gender or race are presented as number and percent of patients with 95% confidence intervals (CI). Percentages are expressed based on the available data for the subgroup relative to the total available data for that variable.

183

Parametric variables were evaluated through a Shapiro-Wilk test of normality with a 184 185 significance cutoff of P<0.01. Non-parametric variables were compared using Mann-Whitney rank sum test, with 95% CIs reported. Categorical variables were evaluated 186 187 using the Fisher exact test, and odds ratios (OR) alongside 95% CIs are presented. All 188 tests were two-tailed and statistical significance was defined as P<0.05. No multiple 189 testing correction was applied. A multivariate linear regression analysis was performed 190 on comorbidities and demographic factors for mortality, and ORs with 95% CIs are 191 presented. Cox proportional hazards analysis for time to death was conducted on 192 comorbidities, demographic factors, and pre-admission medications (angiotensin-193 converting enzyme (ACE) inhibitors and/or angiotensin II receptor blockers (ARBs) and 194 hazard ratios with 95% CIs are presented.

195

# 196 **Results**

197

1,070 patients were tested for COVID-19 over a 5-week period. After excluding 292
patients who tested negative and 282 who were treated as outpatients, 496 inpatients
with positive test results and symptoms consistent with COVID-19 were included in this
study.

202

#### 203 **Demographic Information**

204 The median patient age was 70 years (Interguartile Range (IQR), 60 - 78). A majority of 205 patients were in the age range of 61-80 years (53%, 255/483) and a small minority were 206 <40 years old (5%, 25/483). Mortality rates inversely correlated with patient age, with the 207 highest mortality rate recorded for the >80-year age group (65%, 64/99). 88% of the 208 patients were Black (424/481) and the remaining 12% were Other. No difference in 209 mortality rates were found between the two groups. Male-to-female ratio was 1.17:1, with 210 a higher mortality rate for males (53%, 139/260). The mean BMI of patients was 30 kg/m<sup>2</sup> 211 (obese) and no correlation with mortality was found. A majority of patients (81%, 157/194) 212 never smoked and, while not statistically significant, mortality rate increased with any 213 history of smoking (Table 1).

214

#### 215 **Presenting Signs and Symptoms, Comorbidities, and Pre-admission Medication**

Presenting patient complaints grouped based on systemic symptoms were "fever" (42%, headache, weakness, lethargy), respiratory (76%, cough, shortness of breath), gastrointestinal (21%, diarrhea, vomiting), and neurological (16%, altered mental status, seizure, unresponsiveness).

220

Comorbidities were present in 97% (484/496) of patients. The most common 221 comorbidities were hypertension (HT) (84%, 406/484) and diabetes mellitus (DM) (57%, 222 223 276/484), followed by chronic kidney disease (CKD)/end stage renal disease (ESRD) 224 (24%,117/485), hyperlipidemia (16%, 81/496), history of cancer (9%, 44/482), coronary artery disease (CAD) (8%, 40/496), chronic obstructive pulmonary disease (COPD) (7%, 225 226 30/451), and asthma (6%, 28/449). These comorbidities showed correlation with increased mortality except for HT. Autoimmune diseases (38/482) did not affect outcomes 227 228 (Table 2). Patients with CKD/ESRD and on dialysis (11%, 52/485) showed lower mortality 229 (P=0.001) than counterparts with CKD/ESRD without dialysis (13%, 65/485). These

results are notable considering patients with CKD/ESRD suffered higher mean number of comorbidities (mean 4.2) than other patients (mean 3.3, P = <0.001) (Table 3).

232

In multivariate analysis, age >60 years and CAD were independent predictors of mortality. Hemodialysis in patients with CKD/ESRD was an independent predictor of lower mortality (P = 0.007) (Figure 1). Cox proportional hazards analysis for time to death showed that COPD/Asthma (HR: 1.79, P = 0.005) had a significantly higher hazards ratio for death (Figure 2). Additional analysis demonstrated-patients on pre-admission ACE inhibitors (20%, 29/142) and ARBs (25%, 35/142) had a beneficial effect (P = 0.013 and 0.036 respectively).

240

Complications during clinical course in 312 patients were: acute hypoxic respiratory
failure (37%), AKI (15%), cardiogenic shock (18%), neurological shock (5%), sepsis (4%),
and diabetic ketoacidosis (3%).

244

#### 245 Laboratory Data

246 At admission and at 48-96 hr, leukocyte (8.7K/µL, 10.6K/µL) and neutrophil counts 247 (7.3K/µL, 8.9K/µL) were higher (P<0.001) and lymphocyte counts (0.8K/µL) were lower 248 at 48-96 hr (P=0.003) for non-survivors. The median neutrophil: lymphocyte ratio (NLR) 249 was higher both at admission and at the second time point in patients who did not survive 250 (8.5,10, P<0.001). Platelet and hemoglobin were marginally decreased but were not 251 significantly different in survivors and non-survivors. Blood urea nitrogen (BUN) (33, 39 252 mg/dL), creatinine (1.7, 1.6 mg/dL), glucose (182, 163 mg/dL), alkaline phosphatase (66, 253 75 U/L), and aspartate aminotransferase (AST) (52, 64  $\mu$ /L) levels were higher in non-254 survivors at both time points (P<0.001). Bilirubin and total protein were mildly increased 255 in non-survivors, but were within their respective reference ranges. Albumin (3.4, 2.8 g/dL) was lower for non-survivors at both time points (P<0.001). Lactate dehydrogenase 256 257 (551, 638 U/L), C-reactive protein (180, 283 mg/L), and procalcitonin (1.03, 1.68 ng/mL) showed significantly higher serum levels at admission and at 48-96 hr (P = <0.05) for 258 259 non-survivors. D-dimer (3.0 mcg/mL, 7.5 times elevation), prothrombin time (PT) (17.2 sec), and international normalized ratio (1.4 U) were increased in non-survivors at the 260 261 second time point (P<0.05). Activated partial thromboplastin time (aPTT) was not found 262 to be different in the two groups (Table 4).

263

#### 264 Outcomes

Of the 496 hospitalized patients evaluated, 255 survived and 241 (48.5%) died by the end 265 266 of the study. Of 488 patients examined, 154 received invasive mechanical ventilation, of which 134 (87%) died. Patients who received supplemental oxygen therapy via non-267 268 invasive mode suffered a 32% mortality rate (106/334). This also included patients who self-declared "Do Not Intubate" (DNI), "Do not Resuscitate" (DNR) or came to the hospital 269 in severe respiratory distress and died within the first few hours of admission. More than 270 271 one third of admitted patients died within the first three days of admission (38%, 91/241), 272 which was similar for both Blacks (77/206) and Others (13/32) (Figure 3). Average time 273 to death for ventilated patients was 7.5 days, while for non-ventilated patients it was 6.2 274 days from admission.

### 275 **Discussion**

276

This study documents the demographic, clinical features, and outcomes for patients admitted with COVID-19 at an urban hospital located in an underserved majority-Black neighborhood. We also identify indicators available to physicians at two early time points of evaluation to predict outcomes and develop management plans for appropriate levels of care.

282

The Black patient population in our study faces unique obstacles such as linguistic and cultural barriers to care and understudied comorbidities.<sup>10,11</sup> Despite reports that African-Americans face significantly greater mortality from COVID-19, recent studies have examined the clinical outcomes in largely East-Asian or Caucasian cohorts.<sup>10</sup> Here, we present an analysis of 496 consecutively hospitalized patients who had been diagnosed with COVID-19 over a 5-week period at the height of the pandemic in New York City, and have either been discharged or died.

290

291 Older age at admission correlated with higher mortality rate, with the 60+ year age group 292 most at risk, and was an independent risk factor for mortality. Males suffered significantly 293 higher mortality than females, despite identical representation at admission. Recent 294 reports of high plasma concentrations of ACE-2, a receptor for coronavirus, in men may 295 account for higher mortality.<sup>12</sup> Our inpatient population had a mean BMI in the "obese" range, higher than the national average; this finding mirrors higher BMI amongst the Black 296 population nationwide.<sup>13</sup> However, BMI was not an independent predictor of survival; 297 298 higher BMIs were more commonly seen amongst younger patients. Smoking was less prevalent in our patient population than the national average; 4% were current smokers 299 and 15% had guit.<sup>14</sup> We found smoking to be unrelated to poor outcome. 300

301

302 The majority (88%) of our patients were Black. Race was not an independent prognostic factor for survival; higher mortality in our patient population can be attributed to a greater 303 304 number and prevalence of comorbidities common amongst this group. Comorbidities 305 were present in 97% of our patients, and the presence of any comorbidity was a strong predictor of mortality, as noted in other recent studies.<sup>15,16</sup> HT and DM were the two most 306 prevalent preexisting conditions; prevalence of HT (84%) and DM (57%) was 307 considerably higher than previously reported (up to 63% and 36%, respectively).<sup>17–19</sup> In 308 309 the multivariate analysis, coronary artery disease was strongly associated with adverse 310 outcome (OR, 2.45, CI, 1.14 - 5.69, P=0.034), followed by DM (OR, 1.38, CI, 0.91 - 2.11, 311 P=0.13). A 2.5-fold increase in the risk of mortality from COVID-19 in hypertensive patients has been reported, however, this was not discernable in our patients.<sup>18</sup> Although 312 past history of cancer, HT, autoimmune diseases, and immunosuppression were not 313 314 independent predictors of mortality, the combined effect of these comorbidities on multiple 315 organ systems and resultant dysregulation of the immune system likely increases susceptibility to COVID-19.<sup>19,20</sup> 316

317

A notable finding in multivariate analysis was that patients with CKD who were dialyzed early in the course of treatment had better outcomes than those who did not. This group consisted of ESRD patients receiving continued dialysis during hospitalization and

patients with worsening CKD who were started early on dialysis (OR, 0.37, CI, 0.17 - 0.74, 321 322 P=0.007). These findings are notable considering patients with CKD/ESRD had more comorbidities as compared to all other patients in the study. Early-dialysis stands out as 323 324 a potentially beneficial treatment option for patients with CKD/ESRD. It is likely that 325 dialysis removes inflammatory mediators, cytokines, and other effector molecules 326 responsible for the end-organ damage. CKD and ESRD were more prevalent in our 327 patient population (24%) than reported in other studies (between 3% to 8.5%), most likely 328 due to complications from HT and DM.<sup>4,21</sup> Thus, early hemodialysis is critical in Black 329 patients.

330

331 We found laboratory data at admission vital for triaging patients to receive intensive care. CRP, LDH, and procalcitonin were significantly increased at both admission and at 48-96 332 hr in non-survivors, Indicators of AKI, elevated levels of BUN, creatinine, glucose, and 333 334 reduced levels of bicarbonate or albumin were significant predictors of adverse outcome 335 at both initial and secondary time points. These findings correlate with reported tubular, 336 endothelial, and glomerular capillary loop injury, likely the result of direct injury or systemic 337 hypoxia.<sup>22</sup> Hypoproteinemia and hypoalbuminemia in non-survivors may result from renal 338 insufficiency and suboptimal nutritional status in critically-ill patients, or could reflect stressed state.<sup>21</sup> As reported elsewhere, we found hyperglycemia to be a predictor of 339 340 adverse outcome in COVID-19 patients, regardless of their history of diabetes.<sup>23</sup> 341 Multivariate analysis of laboratory data was not performed due to sample size limitations. 342

343 Peripheral blood analysis showed that a high median NLR at admission and at 48-96 hr was an independent predictor of adverse outcome in COVID-19 patients, as had been 344 reported in other studies.<sup>24</sup> The presence of COVID-19 associated coagulopathy (CAC), 345 346 a condition characterized by elevation in fibrinogen and D-dimer levels, high PT, relatively normal aPTT, and mild thrombocytopenia without evidence of microangiopathy, was 347 348 confirmed in our study.<sup>25</sup> The mechanisms underlying CAC remain poorly understood, 349 but it can possibly result from activation of extrinsic coagulation pathway, leading to 350 excess consumption of Factor-VII following endothelial cell infection by the virus.<sup>26,27</sup> Elevated D-dimer levels at the second evaluation time point were associated with higher 351 352 mortality, likely reflecting coagulation activation from sepsis, "cytokine-storm", or 353 impending organ failure.

354

By the end of our 5-week study, 48.5% of the inpatients had died, including 87% of 355 patients who received invasive mechanical ventilation. Reported mortality rates from 356 357 other retrospective cohort studies ranged from 21% (New York metropolitan area) to 26% (Lombardy region, Italy) and 33% (UK).<sup>4,6,28</sup> Our mortality rate was elevated relative to 358 359 other studies, which we believe is due to the largely poor and disadvantaged neighborhood that our hospital serves. Race was not found to be an independent 360 predictor of mortality. The high mortality rate from COVID-19 from this predominantly 361 362 Black neighborhood demonstrates the large racial disparity in outcomes between these 363 patients and their counterparts elsewhere.

364

Our study has limitations. It examined a predominantly Black patient cohort, which makes comparisons to other races and ethnicities difficult to quantify. This study was carried out

over a five week period at the height of the pandemic in New York City, admissions were
 restricted to the most seriously ill and hospital resources were under strain, which may
 have contributed to an increase in overall mortality rates. As knowledge and
 understanding of COVID-19 was developing during March and early April, complete
 laboratory studies were not systematically ordered for all patients.

372

# 373 Conclusions

374

375 In our predominantly Black cohort we have recorded a mortality rate from COVID-19 376 which is significantly greater than that reported in other studies. While race was not an 377 independent predictor of death, this population had a greater burden of comorbidities than 378 the national average and the prevalence of these chronic comorbidities contributed to 379 both disease severity and higher mortality. Our study identified that early escalation of 380 care is important in patients from minority neighborhoods as one third of the admitted 381 patients die within the first three days-of admission. Laboratory indicators at admission 382 are predictors of outcome and can be utilized by physicians to triage patients and monitor 383 disease course. As early dialysis in patients with chronic renal insufficiency showed 384 considerable benefit, we believe early dialysis in patients with renal disease can improve 385 outcomes.

386

#### 387 Abbreviations

388 ACE, angiotensin converting enzyme; AKI, Acute Kidney Injury; aPTT, activated partial 389 thromboplastin time; Alk Phosphatase, alkaline phosphatase; ALT, alanine 390 aminotransferase; ARB, angiotensin II receptor blockers; ARDS, acute respiratory 391 distress Syndrome: AST, aspartate aminotransferase; BUN, blood urea nitrogen; BMI, 392 body mass index; CAC, COVID-19 associated coagulopathy; CAD, coronary artery 393 disease; CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive 394 pulmonary disease; CRP, C-reactive protein; DM, diabetes mellitus; DNI, do not intubate; 395 DNR, do not resuscitate; ESRD, end stage renal disease; HIV, human immunodeficiency 396 virus; HT, hypertension; INR, international normalized ratio; IQR, interguartile range; LDH. lactate dehydrogenase: NLR. neutrophil:lymphocyte ratio: OR. odds ratio: PT. 397 prothrombin time; rtPCR, real time polymerase chain reaction; SUNY, State University of 398 New York; UK, United Kingdom. 399

400

# 401 Legends to Tables and Figures

402

Figure 1. Multivariate logistic regression analysis of the demographic characteristics and
 comorbidities for mortality. The 95% confidence intervals (CIs) of the odds ratios have not
 been adjusted for multiple testing and thus do not suggest definitive effects. BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
 ESRD, end-stage renal disease.

408

Figure 2. Cox Proportional Hazards analysis on time to death, performed on demographic
 characteristics and comorbidities.

411

Figure 3. Days from admission to death of 241 consecutive inpatients. More than one
third of patients (91/241) died within three days of admission for both Blacks (77/206) and
others (13/32). Race was not recorded in 15 patients.

415

Table 1. Demographic characteristics of patients admitted for treatment. The *P value* is
calculated between patients who survived and did not survive. BMI, body-mass index; CI,
confidence interval

419

Table 2. Comorbidities among patients admitted for treatment. The *P value* is calculated
between patients who survived and did not survive. CKD, chronic kidney disease; COPD,
chronic obstructive pulmonary disease; ESRD, end-stage renal disease

423

**Table 3.** Patients with CKD and/or ESRD had a higher mean number of comorbidities
than all patients. CKD, Chronic kidney disease; ESRD, end-stage renal disease.

426

Table 4. Laboratory data of 281 inpatients at admission and at a secondary time point
between 48 and 96 hours of admission. Median and interquartile ranges are presented.
The *P value* is calculated between patients who survived and did not survive. aPTT,
activated partial thromboplastin time; Alk Phosphatase, alkaline phosphatase; ALT,
alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen;
CI, confidence interval; CRP, C-reactive protein; INR, international normalized ratio; LDH,
lactate dehydrogenase; PT, prothrombin time.

434

# 435 **Declarations**

- 436
- 437 Ethics Approval and Consent to Participate: SUNY Downstate Institutional Review
  438 Board [1587476-1].
- 439 **Consent for Publication:** Not applicable
- 440 Availability of Data and Materials: The datasets used and/or analyzed during the

441 current study are available from the corresponding author on reasonable request.

442 **Competing Interests:** The authors declare that they have no competing interests

- 443 **Funding:** Not applicable
- 444 Author Contributions: RG and MAH conceived and designed the study. RG, RA, and
- 445 MAH designed the statistical analysis plan. RG, RA, and MAH analyzed the data and
- 446 developed the figures and tables. RG, ZB, AJ, DW, JD, MA, and DYE collected data
- 447 from electronic health records. CFB, JL, RC, and AB provided clinical consultation
- throughout the study course. All authors contributed intellectual content during the
- 449 drafting and revision of the work and approved the final version.
- 450 Acknowledgements: Not applicable
- 451
- 452
- 453
- 454
- 455

# References

- 1. WHO Director-General's opening remarks at the media briefing on COVID-19 11 March 2020 [Internet]. [cited 2020 May 23]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-themedia-briefing-on-covid-19---11-march-2020
- 2. Cases in the U.S. | CDC [Internet]. [cited 2020 May 16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html
- 3. U.S. Census Bureau QuickFacts: New York city, New York [Internet]. [cited 2020 May 28]. Available from: https://www.census.gov/quickfacts/newyorkcitynewyork
- 4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA [Internet]. 2020 Apr 22 [cited 2020 Apr 23]; Available from:

http://jamanetwork.com/journals/jama/fullarticle/2765184

- 5. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020 26;368:m1091.
- Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv [Internet]. 2020 Apr 28 [cited 2020 May 23];2020.04.23.20076042. Available from: https://www.medmin.org/content/10.1101/2020.04.23.20076042v1
- https://www.medrxiv.org/content/10.1101/2020.04.23.20076042v1
- 7. Yancy CW. COVID-19 and African Americans. JAMA. 2020 Apr 15;
- 8. East Flatbush Neighborhood Profile [Internet]. [cited 2020 May 23]. Available from: https://furmancenter.org/neighborhoods/view/east-flatbush
- 9. R: The R Project for Statistical Computing [Internet]. [cited 2020 Apr 23]. Available from: https://www.r-project.org/
- 10. Dorn A van, Cooney RE, Sabin ML. COVID-19 exacerbating inequalities in the US. The Lancet [Internet]. 2020 Apr 18 [cited 2020 May 15];395(10232):1243–4. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30893-X/abstract
- Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. J Racial Ethn Health Disparities [Internet]. 2020 Apr 18 [cited 2020 May 15];1–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166096/
- Sama IE, Ravera A, Santema BT, van Goor H, ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors. Eur Heart J [Internet]. 2020 May 14 [cited 2020 May 16];41(19):1810–7. Available from: http://academic.oup.com/eurheartj/article/41/19/1810/5834647
- Fryar CD, Kruszon-Moran D, Gu Q, Ogden CL. Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States, 1999-2000 Through 2015-2016. Natl Health Stat Rep. 2018;(122):1–16.
- 14. Creamer MR. Tobacco Product Use and Cessation Indicators Among Adults United States, 2018. MMWR Morb Mortal Wkly Rep [Internet]. 2019 [cited 2020 May 15];68. Available from: http://www.cdc.gov/mmwr/volumes/68/wr/mm6845a2.htm

- 15. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging. 2020 Apr 8;12(7):6049–57.
- Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J [Internet]. 2020 Jan 1 [cited 2020 May 16]; Available from: https://erj.ersjournals.com/content/early/2020/03/17/13993003.00547-2020
- Garg S. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1– 30, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2020 May 16];69. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm
- 18. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020 30;130(4):304–9.
- 19. Leoncini G, Viazzi F, Storace G, Deferrari G, Pontremoli R. Blood pressure variability and multiple organ damage in primary hypertension. J Hum Hypertens. 2013 Nov;27(11):663–70.
- 20. Restrepo MI, Sibila O, Anzueto A. Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis. 2018 Jul;81(3):187–97.
- Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu H-Y, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int [Internet]. 2020 Apr 9 [cited 2020 May 16];0(0). Available from: https://www.kidneyinternational.org/article/S0085-2538(20)30369-0/abstract
- 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl. 2020 15;395(10223):497–506.
- 23. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Apr 12;
- 24. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020 Apr 10;
- 25. COVID-19 and Coagulopathy Hematology.org [Internet]. [cited 2020 May 16]. Available from: https://www.hematology.org:443/covid-19/covid-19-and-coagulopathy
- 26. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005 May 24;111(20):2605–10.
- Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet Lond Engl. 2020 02;395(10234):1417–8.
- 28. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 06;

Variable	Patients	Survivors	Non-survivors	Odds Ratio (95% CI)	P value
Age - median	70	66	73.5	NA (-10.00 5.00)	<0.001
Age ranges	No./total no. (%)	no. (%)	no. (%)		
+80 yr.	99/483(20)	35 (35)	64 (65)	2.20 (1.36 - 3.60)	<0.001
71-80 yr.	131/483(27)	53 (40)	78 (60)	1.76 (1.15 - 2.71)	<0.001
61-70 yr.	124/483(26)	63 (51)	61 (49)	0.99 (0.64 - 1.52)	0.84
51-60 yr.	66/483(14)	46 (70)	20 (30)	0.39 (0.21 - 0.71)	<0.001
41-50 yr.	38/483 (8)	27 (71)	11 (29)	0.39 (0.17- 0.84)	0.003
0-40 yr.	25/483 (5)	21 (84)	4 (16)	0.18 (0.04 - 0.55)	<0.001
Race/Ethnicity	no./total no. (%)	no. (%)	no. (%)		
Black	424/481 (88)	218 (51)	206 (49)	0.73 (0.40 - 1.33)	0.32
Others	57/481 (12)	25 (44)	32 (56)	1.35 (0.74 - 2.47)	0.32
Sex	no./total no. (%)	no. (%)	no. (%)		
Male	260/482 (54)	121 (47)	139 (53)	1.45 (0.99 - 2.11)	0.44
Female	222/482 (46)	124 (56)	98 (44)	0.68 (0.47 - 1.00)	0.44
BMI mean	30	31	29	NA (-2.60 - 1.00)	0.40
BMI	no./total no. (%)	no. (%)	no. (%)		
<29.9	132/235 (56)	45 (34)	87 (66)	1.32 (0.75 - 2.34)	0.34
>30	103/235 (44)	42 (40)	61 (60)	0.75 (0.43 - 1.32)	0.34
Smoking Status	no./total no. (%)	no. (%)	no. (%)		
Non-smoker	157/193 (81)	80 (51)	77 (49)	0.73 (0.33 - 1.60)	0.46
Past/current smoker	36/193(19)	15 (42)	21 (58)	1.46 (0.66 - 3.30)	0.35

#### **Table 1.** Demographic Characteristics of COVID-19 inpatients.

#### Table 2. Comorbidities in COVID-19 inpatients.

Comorbidities	All Patients no./total (%)	Survivors no. (%)	Non- survivors no. (%)	Odds Ratio (95% CI)	P value
Asthma	28/449 (6)	9 (32)	19 (68)	2.44 (1.02 - 6.27)	0.03
Autoimmune disease	38/482 (8)	22 (58)	16 (42)	0.77 (0.36 - 1.59)	0.50
History of cancer	44/482 (9)	14 (32)	30 (68)	2.52 (1.25 - 5.29)	<0.001
COPD	30/451 (7)	14 (47)	16 (53)	1.32 (0.58 - 3.01)	0.057
Coronary Artery Disease	40/496 (8)	10 (25)	30 (75)	3.47 (1.60 - 8.16)	<0.001
Congestive Heart Failure	22/496 (4)	13 (59)	9 (41)	0.72 (0.26 - 1.86)	0.51
CKD without dialysis	65/485 (13)	24 (37)	41 (63)	2.01 (1.14 - 3.61)	0.011
CKD/ESRD with dialysis	52/485 (11)	38 (73)	14 (27)	0.35 (0.17 - 0.69)	0.001
Diabetes mellitus	276/484 (57)	132 (48)	144 (52)	1.48 (1.01 - 2.17)	0.03
Hyperlipidemia	81/496 (16)	34 (42)	47 (58)	1.57 (0.94 - 2.63)	0.06
Hypertension	406/484 (84)	207 (51)	199 (49)	1.31 (0.78 - 2.21)	0.32
Immune suppression	40/475 (8)	26 (65)	14 (35)	0.55 (0.25 - 1.13)	0.09
All patients ≥ 1 Comorbidities	484/496 (97)	252/255 (99)	232/241 (96)	-	-

**Table 3.** Mean number of comorbidities in patients with chronic kidney diseases and/or

 end-stage renal disease relative to all patients

Patient group (no.)	Comorbidities (mean)	P value
CKD/ESRD (117/485)	4.2	< 0.001
All patients (485)	3.3	

**Table 4.** Laboratory Data at admission and at a secondary time point between 48 and 96 hours of admission in hospitalized patients.

Laboratory values	Time of determination	Survivors	Non-survivors	95% CI	<i>P</i> value
(reference range)	(n)	Median (Inter Quartile Range)			
Hematologic param	neters				
Homoglobin	At admission (281)	12.3(11.0 -14.0)	12.7 (11.3-14.3)	-0.9 - 0.1	0.13
(12-16 g/dL)	48 – 96 hr (224)	12.0 (10.15 - 13.1)	11.7 (10.5-13.3)	-0.6 - 0.5	0.83
Leukocyte count	At admission (280)	7.1 (5.4 - 9.3)	8.7 (6.5-11.4)	-2.40.7	<0.001
(0.0 10.0 17 µ2)	48 – 96 hr (224)	6.5 (5.1-9.4)	10.6 (7.8-14.3)	-4.92.7	<0.001
Neutrophil Count	on admission (265)	5.8 (3.8-7.8)	7.3 (4.9-10.0)	-2.50.9	<0.001
(1.7 – 7 K) µL)	$\frac{1}{48 - 96 \text{ hr} (201)} \qquad 5.4 (3.4-7.6) \qquad 8.9 (6.4-12.5)$	8.9 (6.4-12.5)	-4.8, - 2.5	<0.001	
Lymphocyte count	on admission (255)	0.9 (0.7-1.1)	0.8 (0.6-1.1)	-5.4e5, 0.2	0.06
(0.9-2.9 K/μL)	48 – 96 hr(201)	1.0 (0.8-1.3)	0.8 (0.5-1.2)	0.1 - 0.3	0.003
Neutrophil	on admission (255)	5.4 (3.7-8.1)	8.5 (5.3-13.9)	-3.91.5	<0.001
(NLR)	48 – 96 hr (200)	4.7 (3.3-7.0)	10.0 (6.3-19.5)	-7.13.5	<0.001
Eosinophil count	on admission (250)	0.03 (0.01-0.07)	0.01 (0.01-0.04)	0.01 - 0.02	<0.001
(0.0-0.8 K/μL)	48 – 96 hr (199)	0.05 (0.02-0.1)	0.01 (0.01-0.04)	0.01 - 0.03	< 0.001
Platelet count	on admission (278)	204 (160-267)	201 (148-263)	-13.0 - 26.9	0.48

(130-400 K/μL)	48 – 96 hr (221)	5 hr (221) 231 (153-340) 199 (150-280)		-7.0 - 53.9	0.12
Blood Chemistry				·	
Sodium	on admission (282)	136 (133-138)	135 (132-141)	-2.0 - 1.0	0.51
(136-145 mmol/L)	48 – 96 hr (232)	231 (153-340)199 (150-280) $-7.0 - 53.9$ $-7.0 - 53.9$ 136 (133-138)135 (132-141) $-2.0 - 1.0$ $-7.0 - 5.9 - 2.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0 - 5.0 - 5.0$ $-7.0 - 5.0 - 5.0 - 5.0 - 5.0 - 5.0$ $-7.0 - 5.0 -$	<0.001		
Potassium	on admission (281)	4.2 (3.8-4.8)	4.2 (3.8-4.8) 4.4 (3.9-5.0)		0.05
(3.5-5.1 mmol/L)	48 – 96 hr (230)	4.3 (4.0-4.6)	4.4 (3.9-5)	199(150-280)       -7.0 - 53.9       0.1         135(132-141)       -2.0 - 1.0       0.1         142(137-147)       -5.9 - 2.0       0.1         4.4(3.9-5.0)       -0.4 - 4.9e-5       0.0         4.4(3.9-5.0)       -0.4 - 5.2e-5       0.0         22(19-26)       1.0 - 4.9       0.0         21(18-24)       1.6 - 5.0       0.0         100(96-105)       -3.9 - 3.5e-5       0.0         107(102-113)       -8.0 - 3.0       0.0         2.2 (1.9 - 2.6)       -0.30 - 7       0.0         2.3 (19-54)       -0.4 - 0.2       0.0         33 (19-54)       -14.0 - 5.0       0.0         33 (19-54)       -0.5 - 0.1       0.0         1.6 (1.1 - 2.9)       -0.6 - 0.1       0.0         1.63 (119-269)       -72.9 - 35.9       0.0         1.63 (119-269)       -70.9 - 1.0       0.0         1.64 (37.7 - 106.2)       -29.0 - 8.0       0.0         34 (22-57)       -10.0 - 2.0       0.0         34 (22-57)       -10.0 - 2.0       0.0         0.6 (0.5 - 0.8)       -0.1 - 5.0e-5       0.0         0.6 (0.5 - 0.8)       -0.1 - 5.0e-5       0.0         0.6 (0.5 - 0.9)       -0.2 - 5.4e-       <	0.05
Bicarbonate	on admission (194)	25 (22-30) 22 (19-26)		1.0 - 4.9	0.001
(23.0 20.0 minoly E)	48 – 96 hr (141)	24 (21-28) 21 (18-24)		1.6 - 5.0	<.0.00 1
Chloride	on admission (280)	100 (94-103)	100 (96-105)	-3.9 - 3.5e-5	0.09
(98-107 mmol/L)	48 – 96 hr (230)	102 (96-106)	107 (102-113)	-8.03.0	< 0.001
Magnesium	on admission (155)	2 (1.8-2.2)	2.2 (1.9-2.6)	-0.30 2.9e-5	0.014
(1.9-2.7 mg/dL)	48 – 96 hr (160)	2.2 (1.8-2.3)	2.4 (2.1-2.7)	-0.40.2	< 0.001
BUN (7-25 mg/dL)	on admission (280)	22 (14-37) 33 (19-54)		-14.05.0	<0.001
	48 – 96 hr (230)	19 (13-39) 39 (23-66)		-22.010	<0.001
BUN (7-25 mg/dL) Serum creatinine (0.7-1.3 mg/dL)	on admission (281)	1.2 (1.0-2.3)	1.7 (1.2-2.5)	-0.50.1	0.008
	48 – 96 hr (232)	1.2 (0.8-2.2) 1.6 (1.1-2.9)		-0.60.1	0.003
Glucose – random	on admission (281)	128 (104-184)	182 (129-275)	-61.023.0	<0.001
(70-99 mg/dL)	48 – 96 hr (235)	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	<0.001		
AST	on admission (279)	40 (26-65)	(26-65) 52 (38-83)		<0.001
(13-39 μ/L)	48 – 96 hr (219)	49 (28-66)	64 (37.7-106.2)	-29.08.0	< 0.001
ALT	on admission (286)	24 (16-38) 29 (19-44)		-7.0 - 0.1	0.11
(7-52 μ/L)	48 – 96 hr (219)	28 (17-52)	34 (22-57)	-10.0 - 2.0	0.22
Alk Phosphatase	on admission (279)	64 (49-78)	66 (54-96)	-15.01.0	0.02
(34-104 U/L)	48 – 96 hr (218)	59 (46-78)	75 (52-111)	-27.07.0	< 0.001
Bilirubin	on admission (275)	0.5 (0.4-0.8)	0.6 (0.5-0.8)	-0.1 - 5.0e-5	0.28
(0.3-1 mg/dL)	48 – 96 hr (214)	0.5 (0.4-0.8)	0.7 (0.59)	-0.25.4e- 5	0.002
Total protein	on admission (277)	7 (6.5-7.3)	6.7 (6.4-7.2)	-2.6e-5 - 0.3	0.12

(6-8.3 g/dL)	48 - 96 hr (214)	6.2 (5.9-6.6)	6 (5.5-6.7)	-6.0e-5 - 0.4	0.10
Albumin	on admission (278)	3.6 (3.2-4.0)	3.4 (3.1-3.6)	0.1 - 0.3	<0.001
(3.5 - 5.7 g/dL)	48 – 96 hr (218)	3.0 (2.7-3.2)	2.8 (2.5-3.0)	0.1 - 0.3	<0.001
LDH	on admission (201)	379 (280-500) 551 (411-743)		106.0 - 22849	<0.001
(14-271 U/L)	48 – 96 hr (82)	406 (278-553)	638 (444.5-867)	106.9 - 339.0	<0.001
CRP	on admission (201)	117 (63-197)	180 (128-283)	-97.036.9	< 0.001
(<10 mg/L)	48 – 96 hr (85)	96 (41-185)	283 (188-338)	-200.0 88.9	<0.001
Troponin I	on admission (170)	0.03 (0.02-0.12)	0.08 (0.02-0.21)	3.6e-5 - 0.06	0.010
(<=0.15 ng/mL)	48 – 96 hr (61)	0.11 (0.02-0.26)	0.15 (0.06-0.40)	-0.03 - 0.18	0.30
Ferritin	on admission (190)	654.5 (303-1151) 955 (539.0-2114.6)		118.5 - 566.5	0.002
(14-233 ng/mL)	48 – 96 hr (95)	768.5 (439-1821) 1614.1 (499.7- 2801.5)		-37.3, - 1036.7	0.08
Procalcitonin (0-0.10 ng/mL)	on admission(172)	0.32 (0.10-0.96)	0.32 (0.10-0.96) 1.03 (0.36-3.78)		<0.001
	48 – 96 hr (69)	0.34 (0.25-2.47)	1.68 (0.41-7.35)	4.75e-5 - 2.77	0.049
D-dimer	on admission (50)	3.3 (1.3-5.2) 1.5 (0.5-5.2)		-1.02 - 2.6	0.39
<0.4 mcg/ml	48 – 96 hr (43)	0.5 (0.5-1.5)	0.5 (0.5-1.5) 3.0 (1.1-7.5)		<0.001
Coagulation Param	eters				
aPTT	on admission (126)	29.9 (28.4-32.4)	29.0 (26.9-33.6)	-1.9 - 1.5	0.68
(25.4-38.6 sec)	48 – 96 hr (44)	30.7 (28.0-36.2)	31.1 (27.9-39.0)	-6.3 - 6.3	0.99
РТ	on admission (113)	13.0 (12.2-13.7)	13.0 (12.2-13.7) 13.5 (12.6-15.4)		0.04
(10.8-13.7 sec)	48 - 96 hr(43)	13.1 (11.9-15.2)	17.2 (13.3-20.2)	4.94e-5 - 6.7	0.04
	on admission (113)	1.1 (1.0-1.1)	1.1 (1.0-1.3)	-7.12e-6 - 0.10	0.07
	48 – 96 hr (41)	1.0(1.0-1.2)	1.4 (1.1-1.6)	7.49e-6 - 0.50	0.02

#### Figure 1.

Variable		Ν	Odds ratio		р
Race	Black	400	, in the second se	Reference	
	Other	52	⊢¦∎	1.47 (0.78, 2.81)	0.232
Age > 60		452	⊢∎→	2.50 (1.52, 4.18)	<0.001
Sex	Male	205	•	Reference	
	Female	247	; ∰∎⊒⊸	1.43 (0.95, 2.15)	0.088
Coronary Artery Disease		452		2.45 (1.14, 5.69)	0.028
Hyperlipidemia		452		1.21 (0.71, 2.09)	0.477
Diabetes		452	₽ <mark>,</mark> ₩,	1.38 (0.91, 2.11)	0.133
Hypertension		452	<b>⊢</b> ∰	0.96 (0.53, 1.74)	0.890
COPD/Asthma		452	÷∎	1.56 (0.84, 2.92)	0.161
Autoimmune Diseases		452	⊢ <b>₽</b> →	0.94 (0.43, 2.04)	0.871
History of Cancer		452	<u>¦</u> _∎	1.87 (0.92, 3.97)	0.089
Immunocompromised		452	⊢₋	0.79 (0.30, 1.96)	0.612
CKD/ESRD with Dialysis		452	⊢∎→	0.37 (0.17, 0.74)	0.007
<b>Congestive Heart Failure</b>		452	·	0.92 (0.34, 2.40)	0.859

#### Figure 2.

Variable		N	Hazard ratio		р
Race	Black	191	<b>•</b>	Reference	
	Other	30	⊢ <b>_</b> ∎1	1.08 (0.72, 1.62)	0.724
Age		221	<b>•</b>	1.01 (1.00, 1.03)	0.078
Sex	Male	91	<b>M</b>	Reference	
	Female	130	⊢ <b>∎</b> ¦	0.83 (0.61, 1.11)	0.210
Coronary Artery Disease		221	<b>⊢_</b> ∰	1.04 (0.64, 1.68)	0.882
Hyperlipidemia		221	+ <b>+</b> - <b>■</b> +	1.29 (0.90, 1.85)	0.171
Diabetes		221	<b>⊢</b> ∰1	1.07 (0.79, 1.44)	0.670
Hypertension		221	⊢ <b></b>	1.05 (0.70, 1.59)	0.814
COPD/Asthma		221	·	1.79 (1.20, 2.68)	0.005
Autoimmune Diseases		221	<b>∎</b>	0.89 (0.51, 1.56)	0.685
History of Cancer		221	⊢ <b>≜</b>	0.99 (0.65, 1.51)	0.970
Immunocompromised		221		1.27 (0.59, 2.73)	0.543
CKD/ESRD with Dialysis		221		0.51 (0.25, 1.06)	0.070
Congestive Heart Failure		221	· · · · · · · · · · · · · · · · · · ·	1.19 (0.55, 2.57)	0.653
			0.5 1 2		

Figure 3.

